



Celsion Appoints Marianne Lambertson as Vice President of Communications and Investor Relations

September 17, 2018

***Lambertson brings executive experience to the newly created position,
reinforcing Celsion's commitment to its strategic communications
and investor relations objectives***

LAWRENCEVILLE, N.J., Sept. 17, 2018 (GLOBE NEWSWIRE) -- [Celsion Corporation](#) (NASDAQ: CLSN), an oncology drug development company, today announced the appointment of Marianne Lambertson as Vice President of Communications and Investor Relations effective September 17, 2018. Ms. Lambertson most recently held the position of Vice President, Corporate Communications, Investor Relations/Public Relations at Verastem Oncology, a development-stage biopharmaceutical company. Prior to this, she served as Vice President, Strategic Development at Pernix Therapeutics, Vice President, Specialty Medicine at Bayer Healthcare, and held senior global positions at Altana Pharma AG and Elan Pharmaceuticals.

"We are pleased to welcome Ms. Lambertson to our organization, as she brings broad experience in both investor relations and commercialization for U.S. and global bio-pharmaceutical businesses," said Michael H. Tardugno, Celsion's Chairman, President and Chief Executive Officer. "Ms. Lambertson's extensive capital market and communications experience across a range of therapeutic areas and geographies provide relevant and invaluable strategic insight as we move forward with our ThermoDox[®] and GEN-1 programs, advancing toward commercialization in the U.S. and around the world."

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox[®], a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer. The pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: <http://www.celsion.com>

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time, and risk of failure of conducting clinical trials; the need for Celsion to evaluate its future development plans; possible acquisitions or licenses of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in Celsion's periodic reports and prospectuses filed with the Securities and Exchange Commission. Celsion assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

###

Investor Contact

Argot Partners
Sam Martin
212-600-1902
Sam@argotpartners.com
Celsion Corporation
Jeffrey W. Church
Senior Vice President & CFO
609-482-2455
jchurch@celsion.com



Source: Celsion CORP